Trials / Completed
CompletedNCT03672097
Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)
Phase IV, Non-comparative, Open Label, Multicenter, 28-Week Switching Study of Prasugrel Maintenance Dose From Clopidogrel in Patients With Acute Coronary Syndrome (ACS) Who Underwent a Percutaneous Coronary Intervention (PCI) in Taiwan
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 204 (actual)
- Sponsor
- Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This Phase IV, multicenter trial is designed to assess the efficacy of prasugrel in preventing the formation of blood clots in Taiwanese patients with ACS who have been treated with PCI.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Prasugrel | Prasugrel, oral tablets, containing 3.75 mg per tablet |
Timeline
- Start date
- 2018-10-16
- Primary completion
- 2020-08-19
- Completion
- 2020-08-19
- First posted
- 2018-09-14
- Last updated
- 2021-11-12
- Results posted
- 2021-11-12
Locations
10 sites across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT03672097. Inclusion in this directory is not an endorsement.